Table 1.
Summary of modeling approach.
| Elements | Description |
|---|---|
| Target population | ZUMA-2 trial population (R/R mantle cell lymphoma following treatment with a BTKi |
| Treatments | Brexucabtagene autoleucel vs. BSC |
| Model design | Partitioned survival mixture cure model for brexucabtagene autoleucel Partitioned survival model for BSC |
| Model inputs | Efficacy (PFS and OS), safety Utility values Treatment-related costs, disease-related costs, end-of-life costs |
| Outcomes of interest |
Costs by category LYs and QALYs Incremental costs, incremental LYs, incremental QALYs Incremental cost/LY and cost/QALY gained |
| Perspective | Canadian healthcare system perspective |
| Health states | Pre-progression survival Post-progression survival Death |
| Time horizon | Canadian healthcare system perspective |
| Discount | 1.5% per year for both costs and outcomes |
| Cycle length | 1 month |
| Year of cost and currency |
2021 Canadian dollar |
| Sensitivity analysis | One-way deterministic sensitivity analyses Probabilistic sensitivity analyses Scenario analyses |
| Programming software |
Microsoft Excel 365 |
Abbreviations: BSC, Best supportive care; BTKi, Bruton’s tyrosine kinase inhibitor; LYs, Life-years; OS, overall survival; PFS, progression-free survival; QALY, quality-adjusted life-year; R/R, relapsed or refractory.